Sun Pharma

Sun Pharma's Baska plant in Gujarat receives OAI status from the US FDA after inspection, adding near-term regulatory uncertainty but not impacting current US supplies

The USFDA conducted an inspection at the company's Baska facility from 8 September 2025 to 19 September 2025 and has subsequently classified the inspection outcome as Official Action Indicated (OAI)

With Mounjaro gaining ground, launch comes just three months before Novo loses patent for semaglutide

The Delhi High Court has allowed Sun Pharma to manufacture and export semaglutide-based drugs to countries where Novo Nordisk holds no patent, but barred sales in India until March 2026

The approval marks a major win for Sun Pharma in its patent dispute with Danish drugmaker Novo Nordisk, the company that manufactures weight loss drug Ozempic

The dispute centres on Novo Nordisk's Indian patents for semaglutide, which it markets globally as Ozempic and Wegovy for Type 2 diabetes and weight management

A unit of Sun Pharmaceutical Industries plans to invest Rs 3,000 crore on a new manufacturing plant in Madhya Pradesh, according to a regulatory filing. The board of Sun Pharma Laboratories Ltd, a wholly-owned subsidiary of the company, has approved the proposal for setting up a greenfield formulations manufacturing facility in the state, the Mumbai-based drug major said in a filing on Tuesday. Shares of Sun Pharma on Wednesday ended 0.43 per cent higher at Rs 1,805.70 apiece on BSE.

Ilumya, a novel biologic treatment that selectively inhibits IL-23, has already established itself as a blockbuster drug internationally, with presence across 35 countries

Technically, the term 'Golden Cross' has bullish implications with short-term support seen moving higher. Apart from Sun Pharma, Aurobindo Pharma and Divi's Labs too witnessed this formation recently.

AstraZeneca Pharma India and Sun Pharmaceutical Industries have formed an exclusive brand partnership to promote and distribute SZC for hyperkalaemia treatment under separate brands

Specialty portfolio powers Q2; Ilumya, Leqselvi, Unloxcyt to anchor next phase

Sun Pharma's Q2FY26 profit rose to Rs 3,118 crore as India, emerging markets, and rest of world drove growth; US revenues fell 4.1% despite strong gains in innovative medicines

Sun Pharma's net profit is expected to come at ₹2,843.4 crore, marking an average decline of 3 per cent Y-o-Y, as against ₹2,932.3 crore in the year-ago period

Shrikant Chouhan, Head of Equity Research at Kotak Securities, has recommended buying shares of Sun Pharma and Indus Towers today

Ambit analysts see HDFC Bank benefiting from accelerating credit growth, normalisation in cost of funds, and focus on high-yield segments like MSME, gold, and unsecured retail loans.

Technical charts show that select pharma stocks are trading with a negative bias and can tumble up to 19% from here. Granules India, however, looks strong on chart and can rally up to 19%.

Pfizer-US trade deal triggers rally in pharma stocks. Nifty Pharma and BSE Healthcare index jumped 1 per cent each; while Nifty 50 and BSE Sensex advanced 0.1 per cent each in Wednesday's early trade.

Analysts say Indian drugmakers may lean on CDMOs, US plants and diversification to safeguard high-value products as Trump's 100% tariff threat looms over patented drugs

The imposition of a 100 per cent tariff by the US on imports of branded and patented pharmaceutical products starting October 1 may not significantly hurt Indian drug makers, with Sun Pharma being exposed to some headline risk but with limited earnings impact, according to analysts. Among Indian companies, only Sun Pharma has sizeable sales from patented drugs in the US (about 17 per cent of 2024-25 revenue), HSBC Global Investment Research said in a report. The US last week announced the imposition of a 100 per cent tariff on branded or patented drugs entering the United States from October 1, except for pharmaceutical companies building manufacturing plants in the US. The exemption covers projects where construction has started, including sites that have broken ground or are under construction. HSBC said Sun Pharma reported global sales of USD 1.217 billion from patented products in FY25, of which the US market accounted for about USD 1.1 billion (85-90 per cent of global sales),

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.